Sign In

Login

Password

Forgot Password ? Sign Up

Undifferentiated pleomorphic sarcoma (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Undifferentiated pleomorphic sarcoma" in English language version.

refsWebsite
Global rank English rank
68nih.gov
4th place
4th place
43doi.org
2nd place
2nd place
16semanticscholar.org
11th place
8th place
2handle.net
102nd place
76th place
1cancer.gov
1,684th place
1,350th place

cancer.gov

doi.org

handle.net

hdl.handle.net

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

  • Fisher C (September 2004). "Myofibrosarcoma". Virchows Archiv. 445 (3): 215–23. doi:10.1007/s00428-004-1038-9. PMID 15173943. S2CID 220565385.
  • Renn A, Adejolu M, Messiou C, Bhaludin B, Strauss DC, Thway K, Moskovic E (December 2021). "Overview of malignant soft-tissue sarcomas of the limbs". Clinical Radiology. 76 (12): 940.e1–940.e16. doi:10.1016/j.crad.2021.08.011. PMID 34607656. S2CID 238357489.
  • Choi JH, Ro JY (January 2021). "The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities". Advances in Anatomic Pathology. 28 (1): 44–58. doi:10.1097/PAP.0000000000000284. PMID 32960834. S2CID 221862064.
  • Kamat NV, Million L, Yao DH, Donaldson SS, Mohler DG, van de Rijn M, Avedian RS, Kapp DS, Ganjoo KN (February 2019). "The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University". American Journal of Clinical Oncology. 42 (2): 166–171. doi:10.1097/COC.0000000000000496. PMID 30557163. S2CID 56178938.
  • Lee K, Song JS, Kim JE, Kim W, Song SY, Lee MH, Chung HW, Cho KJ, Lee JS, Ahn JH (July 2020). "The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions". European Journal of Surgical Oncology. 46 (7): 1287–1293. doi:10.1016/j.ejso.2020.02.029. PMID 32127249. S2CID 212406069.
  • Hornick JL (January 2020). "Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?". Modern Pathology. 33 (Suppl 1): 56–65. doi:10.1038/s41379-019-0388-4. PMID 31653978. S2CID 204886468.
  • Vodanovich DA, Spelman T, May D, Slavin J, Choong PF (September 2019). "Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases". ANZ Journal of Surgery. 89 (9): 1045–1050. doi:10.1111/ans.15348. hdl:11343/286224. PMID 31364245. S2CID 198997759.
  • Ishihara S, Yamada Y, Iwasaki T, Yoshimoto M, Toda Y, Kohashi K, Yamamoto H, Matsumoto Y, Nakashima Y, Oda Y (January 2021). "PD‑L1 and IDO‑1 expression in undifferentiated pleomorphic sarcoma: The associations with tumor infiltrating lymphocytes, dMMR and HLA class I". Oncology Reports. 45 (1): 379–389. doi:10.3892/or.2020.7837. hdl:2324/4474987. PMID 33155664. S2CID 226270021.
  • Liang J, Li S, Li W, Rao W, Xu S, Meng H, Zhu F, Zhai D, Cui M, Xu D, Cai J, Zhang B (November 2021). "CMTM6, a potential immunotherapy target". Journal of Cancer Research and Clinical Oncology. 148 (1): 47–56. doi:10.1007/s00432-021-03835-9. PMID 34783871. S2CID 244132643.
  • Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y (July 2021). "The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma". Journal of Cancer Research and Clinical Oncology. 147 (7): 2003–2011. doi:10.1007/s00432-021-03616-4. PMID 33811537. S2CID 232773534.
  • Orth MF, Gerke JS, Knösel T, Altendorf-Hofmann A, Musa J, Alba-Rubio R, Stein S, Hölting TL, Cidre-Aranaz F, Romero-Pérez L, Dallmayer M, Baldauf MC, Marchetto A, Sannino G, Knott MM, Wehweck F, Ohmura S, Li J, Hakozaki M, Kirchner T, Dandekar T, Butt E, Grünewald TG (February 2019). "Functional genomics identifies AMPD2 as a new prognostic marker for undifferentiated pleomorphic sarcoma". International Journal of Cancer. 144 (4): 859–867. doi:10.1002/ijc.31903. PMID 30267407. S2CID 52883298.
  • Delespaul L, Lesluyes T, Pérot G, Brulard C, Lartigue L, Baud J, Lagarde P, Le Guellec S, Neuville A, Terrier P, Vince-Ranchère D, Schmidt S, Debant A, Coindre JM, Chibon F (February 2017). "Recurrent TRIO Fusion in Nontranslocation-Related Sarcomas". Clinical Cancer Research. 23 (3): 857–867. doi:10.1158/1078-0432.CCR-16-0290. PMID 27528700. S2CID 3756473.
  • Rodrigues GO, Cramer SD, Winer HY, Hixon JA, Li W, Yunes JA, Durum SK (May 2021). "Mutations that collaborate with IL-7Ra signaling pathways to drive ALL". Advances in Biological Regulation. 80: 100788. doi:10.1016/j.jbior.2021.100788. PMID 33578108. S2CID 231908606.
  • Alomari AK, Glusac EJ, McNiff JM (November 2014). "p40 is a more specific marker than p63 for cutaneous poorly differentiated squamous cell carcinoma". Journal of Cutaneous Pathology. 41 (11): 839–45. doi:10.1111/cup.12388. PMID 25263848. S2CID 9053425.
  • Gleason BC, Nascimento AF (February 2007). "HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma". The American Journal of Dermatopathology. 29 (1): 22–7. doi:10.1097/01.dad.0000249888.41884.6c. PMID 17284958. S2CID 20167145.
  • Mazarico Gallego JM, Herrera Juárez M, Paz-Ares L (March 2020). "The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer". Expert Opinion on Drug Safety. 19 (3): 233–242. doi:10.1080/14740338.2020.1736554. PMID 32129104. S2CID 212405175.